*All times are in EST


Fri 29

6:30PM -8:00PM

Welcome reception


Sat 30

8:30AM -8:40AM

Introduction & Meeting Objectives
John Gribben

8:40AM -10:00AM

Session 1:  T-cell lymphoma

Chairs: Laurence de Leval & Francine Foss

  • Genomic profiling for clinical decision making in TCL: Laurence de Leval
  • Translational discovery in PTCL: Giorgio Inghirami
  • 5-azacitidine in follicular helper T-cell lymphomas: François Lemonnier
  • Therapeutic options for the treatment of PTCLs: Francine Foss
  • Targeting signaling pathways in T-cell lymphoma: Steven Horwitz

Panel Discussion

10:00AM -10:20AM


10:20AM -11:40AM

Session 2:  Evolving frontline immune-chemotherapy for MCL and the impact on survival outcomes                                                                                       
Chairs: Stephen Ansell & Elaine Jaffa

  • Biological characteristics of high-risk MCL: Eric Hsi
  • Significance of the TRIANGLE trial for MCL: Marek Trněný
  • Future role of ASCT in MCL: John Kuruvilla
  • Do you need to treat young and old MCL patients differently? Stephen Ansell
  • Novel agents for relapsed MCL: Yucai Wang
  • ViPOR regimen in MCL: Wyndham Wilson

Panel Discussion:
Remaining gaps and perspectives

11:40AM -12:30PM

Session 3: Keynote address
Chair & Introduction: Andreas Rosenwald

  • Emerging role of super-enhancer hypermutation deregulating gene expression
    in DLBCL – pathogenetic and therapeutic implications: Riccardo Dalla-Favera

Panel Discussion

12:30PM -1:30PM


1:30PM -2:40PM

Session 4: New pathogenetic mechanisms and therapeutic targets in DLBCL
Chairs: Riccardo Dalla-Favera & Ash Alizadeh

  • Molecular pathogenesis of germinal center-derived B-cell lymphomas: Laura Pasqualucci
  • Genomic alterations in DLBCL – new relevant pathways and potential therapeutic targets:
    Ken Young
  • Cell-free DNA – mutations for MRD monitoring & epigenetics/fragmentomics for disease detection in various lymphomas: Ash Alizadeh

Panel Discussion

2:40PM -3:00PM


3:00PM -5:10PM

Session 4: Novel Therapies Part 1
Chairs:  John Gribben & Laurie Sehn

  • Novel drug development: an industry perspective; Simon Rule

Industry Panel Discussion

Antibody-drug conjugates:

  • POLARIX – Polatuzumab vedotin: Laurie Sehn
  • Zilovertamab: Sven De Vos
  • Loncastuximab tesirine: Paolo Caimi
  • Camidanlumab: Andrew Davies
  • Brentuximab vedotin: Stephen Ansell
  • Emerging ADCs with novel targets: Juan Pablo Alderuccio

Menin inhibitors

  • BMF-219: Paolo Caimi

 Panel Discussion

Day 1 summary


Sun 01

8:30AM -11:00AM

Session 6: Expanding the CAR platform for NHL
Chairs: David Maloney & Jason Westin

  • Tisa-cel; Stephen Schuster
  • Axi-cel; Sattva Neelapu
  • Liso-cel; David Maloney
  • C-CAR066 & C-CAR039; John Gerecitano
  • Expanding to T cell lymphomas; LaQuisa Hill
  • CB-010: CD19-directed, PD-1 KO, AlloCAR for R/R B-cell lymphomas; James Essell

Panel Discussion (15 min)

  • Repeat CAR-T following failure of a first CD19 CAR-T – does it work?: David Miklos
  • Expanding CAR T-cells as a second-line therapy for LBCL – A paradigm shift?: Jason Westin
  • Allogeneic CAR-T for NHL – fact or fantasy?: Tanya Siddiqi
  • CAR T-cell therapy in the ‘real world’; Lazaros Lekakis
  • Long-term outcomes following CAR-T cell therapy – what do we know so far? James Kochenderfer

Panel Discussion: CAR-T in the real-World Setting

11:00AM -11:20AM


11:20AM -12:50PM

Session 7: Novel Therapies Part 2: BTK inhibitors
Chairs:  Laurie Sehn & Tanya Siddiqi

  • Ibrutinib combinations in younger lymphoma patient; Wyndham Wilson
  • Zanubrutinib; Mazyar Shadman
  • Acalabrutinib; Marek Trněný
  • Pirtobrutinib; Nirav Shah
  • BTK Degraders – NX-2127; Tanya Siddiqi

Panel Discussion

12:50PM -1:50PM


1:50PM -3:40PM

Session 8: Bispecifics for NHL
Chairs: Martin Hutchings & Marion Subklewe

  • CD20/CD3 bispecific antibodies – how to choose? Mazyar Shadman
  • Glofitamab; Martin Hutchings
  • Mosunetuzumab; Laurie Sehn
  • Blinatumomab; Marion Subklewe

Roundtable Discussion

  • Plamotamab; Krish Patel
  • Odronextamab; Krish Patel
  • TNB 486; Ranjit Nair
  • Epcoritamab; Martin Hutchings

Roundtable Discussion                        

3:40PM -3:50PM

Closing remarks
John Gribben